fluoropyrimidine, HER2 positivum,, oxaliplatin, Seagen Inc, tucatinib, Tukysa
Accelerata approbatio a FDA ad tucatinib cum trastuzumab pro cancro colorectali conceditur
Mense Februario 2023, Cibus et medicamentum Administrationis (FDA) approbationem tucatinib (Tukysa, Inc. Seagen) et trastuzumab curationem generis RAS silvestris-typi HER2-positivi colorectalis cancri curando diffudit vel rem.